{
  "id": 16611430,
  "title": "#ESMO26: SystImmune/BMS and Hengrui detail data in EGFR-mutant lung cancer",
  "url": "https://urgent.news/2026/10/26/esmo26-systimmune-bms-and-hengrui-detail-data-in-egfr-mutant-lung",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-26T14:11:34.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/esmo26-systimmune-bms-and-hengrui-detail-data-in-egfr-mutant-lung-cancer/"
  },
  "original_language": "en",
  "account": null,
  "summary": "MADRID — Several drugmakers with antibody-drug conjugates are jockeying for a spot in EGFR-mutant non-small cell lung cancer patients who progress after AstraZeneca’s Tagrisso. And it seems that the most intriguing results are coming out of ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}